Regeneron Pharmaceuticals' Change in Cash rose 2795.47% to $610.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $634.7 million, marking a year-over-year increase of 35510.45%. This contributed to the annual value of $634.7 million for FY2025, which is 35510.45% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Change in Cash of $610.6 million as of Q4 2025, which was up 2795.47% from $497.5 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Change in Cash registered a high of $1.4 billion during Q3 2021, and its lowest value of -$2.0 billion during Q2 2023.
Its 5-year average for Change in Cash is $45.8 million, with a median of $153.4 million in 2022.
In the last 5 years, Regeneron Pharmaceuticals' Change in Cash tumbled by 410627.53% in 2023 and then soared by 57187.5% in 2025.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Change in Cash stood at -$546.8 million in 2021, then grew by 29.52% to -$385.4 million in 2022, then skyrocketed by 249.87% to $577.6 million in 2023, then dropped by 17.38% to $477.2 million in 2024, then grew by 27.95% to $610.6 million in 2025.
Its Change in Cash stands at $610.6 million for Q4 2025, versus $497.5 million for Q3 2025 and -$1.1 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value